We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is ADC Therapeutics SA (ADCT - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
ADC Therapeutics SA is one of 925 individual stocks in the Medical sector. Collectively, these companies sit at #10 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ADCT's full-year earnings has moved 17.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ADCT has gained about 23.2% so far this year. At the same time, Medical stocks have lost an average of 3.6%. This shows that ADC Therapeutics SA is outperforming its peers so far this year.
ALX Oncology Holdings Inc. (ALXO - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 78.8%.
For ALX Oncology Holdings Inc., the consensus EPS estimate for the current year has increased 25.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ADC Therapeutics SA is a member of the Medical - Biomedical and Genetics industry, which includes 444 individual companies and currently sits at #142 in the Zacks Industry Rank. On average, this group has gained an average of 3.6% so far this year, meaning that ADCT is performing better in terms of year-to-date returns. ALX Oncology Holdings Inc. is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to ADC Therapeutics SA and ALX Oncology Holdings Inc. as they could maintain their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is ADC Therapeutics SA (ADCT - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
ADC Therapeutics SA is one of 925 individual stocks in the Medical sector. Collectively, these companies sit at #10 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ADCT's full-year earnings has moved 17.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ADCT has gained about 23.2% so far this year. At the same time, Medical stocks have lost an average of 3.6%. This shows that ADC Therapeutics SA is outperforming its peers so far this year.
ALX Oncology Holdings Inc. (ALXO - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 78.8%.
For ALX Oncology Holdings Inc., the consensus EPS estimate for the current year has increased 25.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ADC Therapeutics SA is a member of the Medical - Biomedical and Genetics industry, which includes 444 individual companies and currently sits at #142 in the Zacks Industry Rank. On average, this group has gained an average of 3.6% so far this year, meaning that ADCT is performing better in terms of year-to-date returns. ALX Oncology Holdings Inc. is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to ADC Therapeutics SA and ALX Oncology Holdings Inc. as they could maintain their solid performance.